Program
IVW-1001
A development code. Also written as “IVW-1001 Ophthalmic Eyelid Wipe 0.2%”, “IVW-1001 Ophthalmic Eyelid Wipe 0.4%” and “IVW-1001 Ophthalmic Eyelid Wipe”.
Its studies are mostly in Dry Eye Syndromes, led by IVIEW Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| IVIEW Therapeutics | 30 open or running | phase 2since May 1, 2024 | May 1, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 1, 2024First study: phase 2 study in Dry Eye SyndromesFirst studyNCT06400459 · 150 enrolled · United States
- Aug 18, 20252 phase 2 studies in Dry Eye SyndromesNCT07140380, NCT07161011
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07161011Dry Eye Syndromes · United States | 2 | Completed | Nov 3, 2025 | 15 |
| NCT07140380Dry Eye Syndromes · United States | 2 | Completed | Oct 8, 2025 | 30 |
| NCT06400459Dry Eye Syndromes · United States | 2 | Completed | Oct 15, 2024 | 150 |
How it is read
Names in the registry
- “IVW-1001 Ophthalmic Eyelid Wipe 0.2%”, 2 entries
- “IVW-1001 Ophthalmic Eyelid Wipe 0.4%”, 1 entry
- “IVW-1001 Ophthalmic Eyelid Wipe”, 1 entry
- “IVW-1001 Ophthalmic Eyelid Wipe 0.1%”, 1 entry
Codes read as this program: IVW1001.
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.